Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-147 for APOL1-mediated proteinuric kidney disease
NL-OMON56156Phase 2Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in APOL1-mediated kidney disease (AMKD) comparing VX-147 with Placebo (2 arms). Primary endpoints: Percent change in urine protein-to-creatinine ratio from baseline at Week 48 and Estimated glomerular filtration rate slope. Started Feb 2023; status: recruiting.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NL-OMON56156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56156.